Scout | Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)

This grant opportunity is for research focused on understanding how host cell death and immune responses work when infected with Mycobacterium tuberculosis (Mtb) or both Mtb and HIV. The goal is to discover immune system targets that can help create new therapies that target the host, rather than the bacteria or virus.

Source

Agency: National Institutes of Health

Sub-agency: National Institute of Allergy and Infectious Diseases

Program: SBIR

Dates

Opportunity Released: August 9, 2022

Open for Submission: August 9, 2022

Submission Deadline: December 7, 2024

Application Window Closes: December 7, 2024

Keywords

Mycobacterium tuberculosis

host cell death pathways

immune responses

Mtb/HIV co-infection

immune targets

host-directed therapies

mechanistic studies

tuberculosis research

infectious diseases

funding opportunity.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers